ReviewMetabolic brain disease2019
Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
Review in Metabolic brain disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Trial
- Pathophysiological mechanisms of fatigue and multidisciplinary management strategies (Review).Experimental and therapeutic medicine · 2026Review
- Clinical efficacy of Jianqiao ancient moxibustion in treating chronic fatigue syndrome: a single-center randomized controlled superiority trial protocol.Frontiers in medicine · 2026Article
- Gut Microbiome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Insights into Disease Mechanisms.International journal of molecular sciences · 2025Review
- Safety and Effectiveness of an Exercise-Based Telerehabilitation Program in Myalgic Encephalomyelitis and Post COVID Syndrome: Protocol for a Randomized Controlled Clinical Trial.Healthcare (Basel, Switzerland) · 2025Article
- Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitchJournal of translational medicine · 2025Article
- Assessment of the Gut Microbiome in Patients with Coexisting Irritable Bowel Syndrome and Chronic Fatigue Syndrome.Nutrients · 2025Article
- Impact of Tai Chi Therapy on Fatigue and Cognitive Function in Individuals With Chronic Fatigue Syndrome: Protocol for a Pilot Randomized Controlled Trial.JMIR research protocols · 2025Article
- Comprehensive Bioinformatics Analysis Reveals the Role of Shared Cuproptosis- and Ferroptosis-Related DEG DLD in Abdominal Aortic Aneurysm.Journal of cellular and molecular medicine · 2025Article
- Core features and inherent diversity of post-acute infection syndromes.Frontiers in immunology · 2025Review
- Frontal-striatal glucose metabolism and fatigue in patients with multiple sclerosis, long COVID, and COVID-19 recovered controls.Experimental brain research · 2024Article
- Article
- Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives.Journal of clinical medicine · 2024Review
- Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.Biochemistry · 2024Article
- Investigating Antibody Reactivity to the Intestinal Microbiome in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Feasibility Study.International journal of molecular sciences · 2023Article
- Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine.Molecular psychiatry · 2023Review
- Higher Stress in Oncology Patients is Associated With Cognitive and Evening Physical Fatigue Severity.Journal of pain and symptom management · 2023Article
- The Adaptive Force as a Potential Biomechanical Parameter in the Recovery Process of Patients with Long COVID.Diagnostics (Basel, Switzerland) · 2023Article
- Converging Evidence of Similar Symptomatology of ME/CFS and PASC Indicating Multisystemic Dyshomeostasis.Biomedicines · 2023Review
- Chronic fatigue syndrome in caregivers of children with cerebral palsy and affecting factors.Northern clinics of Istanbul · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A model of the development and progression of chronic fatigue syndrome (myalgic encephalomyelitis), the aetiology of which is currently unknown, is put forward, starting with a consideration of the post-infection role of damage-associated molecular patterns and the development of chronic inflammatory, oxidative and nitrosative stress in genetically predisposed individuals. The consequences are detailed, including the role of increased intestinal permeability and the translocation of commensal antigens into the circulation, and the development of dysautonomia, neuroinflammation, and neurocognitive and neuroimaging abnormalities. Increasing levels of such stress and the switch to immune and metabolic downregulation are detailed next in relation to the advent of hypernitrosylation, impaired mitochondrial performance, immune suppression, cellular hibernation, endotoxin tolerance and sirtuin 1 activation. The role of chronic stress and the development of endotoxin tolerance via indoleamine 2,3-dioxygenase upregulation and the characteristics of neutrophils, monocytes, macrophages and T cells, including regulatory T cells, in endotoxin tolerance are detailed next. Finally, it is shown how the immune and metabolic abnormalities of chronic fatigue syndrome can be explained by endotoxin tolerance, thus completing the model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.